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Sequence analysis of the murine gamma-herpesvirus 68 (gHV68) genome previously identified several open reading frames (ORFs) located at
the left end of the viral genome that do not share homology with other known herpesvirus or cellular genes. Here, we show that one of these ORFs,
M4, encodes a secreted glycoprotein that influences the establishment of splenic latency at early times post-infection. We generated a mutant virus
containing a premature translation termination codon in the M4 ORF (M4.STOP), and demonstrated that this mutant virus replicates in vitro
equivalent to wild type and marker rescue (M4.MR) viruses. M4.STOP was also capable of high-titer lytic replication in vivo, but at 16 days post-
infection the establishment of latency in the spleen was significantly impaired. The defect in the establishment of splenic latency was apparent
following either intranasal or intraperitoneal inoculation. In contrast, the M4.STOP mutant did not exhibit a defect in the establishment of latency
in peritoneal cells. These results suggest that M4 mediates an extracellular host-pathogen interaction that impacts the establishment of latent
infection in the spleen, but not the peritoneum.
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The g-herpesviruses include the human pathogens Epstein–
Barr Virus (EBV) and Kaposi’s sarcoma-associated herpesvirus
(KSHV or HHV-8). These viruses establish life-long infection
of the host and are associated with a number of malignancies.
Murine g-herpesvirus 68 (gHV68) is a member of the g2-
herpesvirus subfamily based on genome sequence (McGeoch et
al., 2005; Virgin et al., 1997). gHV68 has proven to be a useful
model for studying the in vivo pathogenesis of g-herpesvirus
infection as it is capable of infecting both inbred and outbred
strains of mice (Sunil-Chandra et al., 1992a, 1992b), and it is
amenable to genetic manipulation after being cloned as a
bacterial artificial chromosome (BAC) (Adler et al., 2000). The0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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College Circle, Toronto, Ontario, Canada M5S 1A8.pathogenesis of gHV68 has been previously reviewed (Nash
and Sunil-Chandra, 1994; Simas and Efstathiou, 1998; Speck
and Virgin, 1999; Virgin and Speck, 1999). Briefly, infection
results in an acute, productive infection of multiple organs and
a CD4+ T-cell dependent splenomegaly (Usherwood et al.,
1996a). Acute virus replication is largely cleared by 2 to 3
weeks post-infection (Tibbetts et al., 2003). Subsequently,
gHV68 is present in its persistent, latent form, during which
time the genome is maintained in infected cells in the absence
of detectable preformed infectious virus. gHV68 establishes a
latent infection in B cells, macrophages, dendritic cells, and
persists in lung epithelial cells (Flano et al., 2000, 2003;
Stewart et al., 1998; Sunil-Chandra et al., 1992a, 1992b; Weck
et al., 1999a, 1999b). Similar to EBV infection, memory B cells
appear to maintain gHV68 latency long-term (Flano et al.,
2002; Willer and Speck, 2003).
Sequence analysis of the gHV68 genome identified 80 ATG
initiated open reading frames (ORFs) predicted to encode
proteins of at least 100 amino acids in length (Virgin et al.,
1997). While the majority of these ORFs were homologous to
known genes present in other g-herpesviruses, a number were
found which have no known cellular or viral homologues.6) 520 – 531
www.e
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nomenclature, and M1 through M4 comprise a unique gene
cluster adjacent to the terminal repeat at the far left end of the
genome. The position of this locus is analogous to the trans-
terminal repeat region found among several g-herpesviruses in
which each virus encodes unique genes thought to impact host
pathogenesis (Virgin et al., 1997). Confirmation of this notion
for gHV68 came with the independent isolation of two deletion
mutants that lack this region. These two viruses, characterized
as gHV68 D9473 (Clambey et al., 2002) and MHV-76 (Macrae
et al., 2001), contain nearly identical genomic structure in which
the first 9.5 kilobases (kb) of coding sequence adjacent to the
terminal repeat is lost, effectively deleting the M1, M2, M3, and
M4 genes along with eight viral tRNA-like genes. Study of the
D9473 mutant demonstrated profound differences in pathogen-
esis, including attenuated acute infection and altered establish-
ment of and reactivation from latency (Clambey et al., 2002).
Systematic genetic mapping in this region became a goal for
understanding the molecular pathogenesis of gHV68 infection.
Several of the phenotypic features of D9473 could be attributed
to the loss of specific gene function within the 9.5-kb deletion.
For example, disruption of the M1 ORF results in an increased
efficiency of reactivation from peritoneal latency (Clambey et
al., 2000), while the M2 ORF was found to be critical for the
establishment of splenic latency following intranasal infection
(Jacoby et al., 2002). In contrast, specific disruption of the M3
ORF did not impact viral latency although it altered the course
of intracranial infection (van Berkel et al., 2002). Certain
features of the D9473 virus could not be explained by these
targeted studies, however, including differences in acute
infection and the persistent defect in splenic latency at late
times post-infection (Clambey et al., 2002). These differences
may result from the combinatorial effects of multiple gene
deletions in the region, or be the result of genes that have not yet
been studied in isolation, including M4. We set about producing
a targeted disruption of the M4 ORF in order to further fine map
the genetic determinants of this locus and determine the role of
M4 in the absence of any other genetic loss of function. During
the course of this study, a role for M4 in vivo was suggested by
its ability to restore some features of gHV68 infection after
recombinant repair of a portion of the 9.5-kb deletion at the left
end of the viral genome (Townsley et al., 2004).
Here, we report an initial characterization of the protein
product encoded by the M4 ORF, and assess the requirement
for the M4 protein during lytic and latent gHV68 infection in
vivo. The M4 transcript was found to be expressed at early
times post-infection and initiates with the second methionine of
the ORF defined by Virgin et al. (1997). The M4 protein was
found to be a secreted glycoprotein, modified by the addition of
hybrid or complex N-linked glycans. In addition, a mutant
virus containing a translation stop codon in the M4 open
reading frame was found to be impaired in the establishment of
splenic latency at early times post-intranasal or intraperitoneal
infection. In contrast, the M4 mutant had no effect on
establishment or reactivation from peritoneal exudates cells
(PECs), demonstrating tissue or cell type-specific requirements
for M4 function.Results
Transcripts corresponding to the M4 ORF are the only species
detected in the M4 region during lytic infection
The M4 transcript has previously been shown to be
expressed with immediate-early kinetics during lytic infection
in vitro (Ebrahimi et al., 2003; Martinez-Guzman et al., 2003;
Townsley et al., 2004). Northern blot analyses were performed
in order to begin to characterize transcriptional activity in the
area of the M4 ORF and determine if any other transcripts
would be likely affected by mutations introduced within the
M4 ORF. Examination of infected cellular RNA with a double
stranded DNA probe that spanned most of the M4 ORF
revealed a predominant species corresponding to the predicted
transcript length of ca. 1.2 kb and a minor species ca. 1.9 kb
(Figs. 1A and B). This transcript was detected as early as 4 h
post-infection and remained detectable throughout the time
course of the experiment. To confirm that this transcript was
specific for M4, single stranded probes complimentary to the
M4 transcript, or transcripts emanating from the alternate
strand, were designed to two distinct locations—immediately
downstream of the predicted ORF start and downstream of the
second ATG codon (Fig. 1A). Only the probe complimentary to
the M4 transcript at the most downstream position (8447–95a-
s) was capable of hybridizing to total infected cellular RNA
(Fig. 1C, third panel), and the banding pattern matched that
observed with the large double-stranded probe shown in Fig.
1B. The single-stranded probe complementary to the M4
coding strand at the upstream position did not hybridize to any
detectable M4 transcript species, nor did either single stranded
probe that was designed to the alternative strand (Fig. 1C).
These data demonstrate that the M4 coding region initiates at
the second methionine in the open reading frame, in agreement
with the findings of Townsley et al. (2004).
The M4 ORF encodes a secreted glycoprotein
To examine the product of the M4 ORF, the M4 coding
sequence was cloned into an expression vector under the
control of the cytomegalovirus immediate-early gene promoter
with an in-frame FLAG epitope tag at the carboxy-terminus of
the M4 ORF (see Materials and methods). This expression
vector was transfected into COS-1 cells and the expression of
M4 protein assayed by Western blot using a FLAG-specific
antibody. Previously reported sequence analysis has suggested
that the M4 gene product contains a signal cleavage site near
the amino-terminus (Alexander et al., 2002). As shown in Fig.
2A, two M4 species were readily detected in the supernatant
(tissue culture medium) of transfected cells, while no FLAG-
tagged M4 species were detectable in cell lysates. In addition, a
FLAG-tagged M3 protein which served as a positive control
(van Berkel et al., 1999) was also observed in the supernatant
but not in cell lysates. The FLAG-tagged viral cyclin was
readily detected in the whole cell lysate, but not in the culture
supernatant, confirming that overexpressed viral protein was
readily detectable in the whole cell lysate and that the presence
Fig. 2. M4 is secreted from mammalian cells and modified by the addition of complex N-linked oligosaccharides. M4, M3, and the viral cyclin (v-cyclin, ORF 72)
were cloned into a FLAG epitope expression vector and transiently transfected into cos-1 cells. (A) Whole cell lysates and cell supernatants were immunoprecipitated
with a-FLAG antibody and detected by Western blot with a-FLAG. M4-FLAG protein was only found in the supernatants of transfected cells, as was the M3-FLAG
protein. The v-cyclin-FLAG protein was only found in transfected cell lysates. (B) Differential susceptibility to modification by endoglycosidases reveals the
presence of complex N-linked oligosaccharide residues. M4-FLAG immunoprecipitated from transfected cell supernatants was digested with EndoH or PNGase.
M4-FLAG was resistant to digestion with EndoH, but susceptible to digestion with PNGase, suggesting that the glycans present on the secreted M4 protein are of the
hybrid or complex variety. The secreted form of M3 has previously been characterized as a 44-kDa protein.
Fig. 1. Northern blot analysis of M4 transcription. (A) Schematic of double and single stranded probes used to assess transcription in the M4 region. The black bar
denotes the 752-bp region corresponding to the double stranded DNA probe used in panel B. The two gray bars represent the 50-bp regions, upstream and
downstream of the second methionine codon (ATG), corresponding to each of the two sets of sense and anti-sense single stranded probes used in part C. (B) NIH
3T12 fibroblasts were infected at a multiplicity of infection (MOI) of 5 and total RNA was harvested at the indicated time points. Northern blot analysis was
performed with a double stranded DNA probe corresponding to genomic coordinates 8672 to 9422 base pairs. A predominant band was detected of approximately
1.2 kb in length. (C) Single-stranded DNA probes corresponding to 50 bp stretches upstream and downstream of the second possible translation initiation codon were
used to analyze total RNA from NIH 3T12 fibroblasts infected for 8 h. Probes were matched for identical G+C content, and both sense (s) and antisense (a-s)
orientations were used (+, infected cells; , mock infection). The banding pattern produced by the probe complimentary to the M4 transcript downstream of the
second ATG codon (arrows) was identical to that produced by the double stranded probe.
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incomplete removal of cellular debris (Fig. 2A).
Both M4 species observed in the supernatant migrate at a
higher molecular weight than the 45 kilodaltons (kDa)
predicted by analysis of the primary sequence, while M3 and
the viral cyclin migrate at their predicted size (45 and 29 kDa,
respectively, Fig. 2A). Inspection of the predicted M4 protein
revealed the presence of seven consensus N-linked glycosyl-
ation sites in the carboxy-terminal half of the protein. To
determine if the discrepancy between the observed and
predicted molecular weight of the secreted protein is the result
of glycosylation, FLAG-tagged protein was immunoprecipi-
tated from transfected cell supernatants and digested with two
separate endoglycosidases, Endoglycosidase H (Endo H) and
Peptide N-Glycosidase F (PNGase). Endo H is a glycosidase
which cleaves only asparagine-linked (N-linked) high mannose
and some hybrid oligosaccharide structures. Glycans contain-
ing other forms of oligosaccharides are resistant to Endo H
digestion, while PNGase cleaves high mannose, hybrid, and
complex oligosaccharides from N-linked glycoproteins. The
M3 protein was used as a control in these reactions, and as
predicted was found to migrate at the same size in denaturing
gels regardless of endoglycosidase treatment (Fig. 2B). The
secreted M4 species were resistant to EndoH treatment, but
treatment with PNGase resulted in a substantial decrease in
molecular weight (Fig. 2B). The deglycosylated protein
appeared as a single band of 45 kDa, as originally predicted,
suggesting that the two higher molecular weight species
represent differentially glycosylated products. Notably, degly-
cosylation also enhanced detection of M4 by the anti-FLAG
antibody, suggesting that glycosylation partially masked
antibody recognition of the C-terminal FLAG epitope. These
results confirm that the secreted M4 protein is modified with
N-linked oligosaccharides of the hybrid or complex variety.
Construction of a cHV68 mutant with a disruption of the M4
open reading frame
In order to study the role of the M4 ORF in the genetic
context of gHV68 infection, we generated a mutant virus
containing a disruption of the M4 ORF (M4.STOP) by allelic
exchange in E. coli. This method has previously been used to
generate gHV68 mutants and is described in detail elsewhere
(Moorman et al., 2003). In the M4.STOP virus, the codon
immediately following the initiating methionine was mutated to
encode a translational termination codon. In addition to the
introduction of a translation stop codon, an extra nucleotide
was inserted following the stop codon to shift the reading frame
of the remaining M4 coding sequence in the event of read-
through of the stop codon (see Materials and methods). The
introduction of these mutations into the viral genome also
resulted in the generation of a novel AclI site, which was used
to confirm the genotype of the M4.STOP mutant by Southern
blot (Fig. 3). To confirm that any observed phenotypes are the
result of the mutation in M4, and not second site mutations
introduced by recombination, a marker rescue virus was
constructed from the M4.STOP mutant that restored the wildtype sequence. Removal of the AclI site was diagnostic of
rescue of the M4 mutation and was confirmed by Southern blot
(Fig. 3).
Following confirmation of the correct genotypes, M4.STOP
and M4.MR BACs were transfected into Vero-Cre cells, which
constitutively express Cre-recombinase, to generate viral
stocks. Expression of Cre-recombinase results in removal of
the BAC vector sequences from the viral genome. While
required for replication of the gHV68 BAC in E. coli, inclusion
of BAC vector sequence results in a virus with an attenuated
phenotype in vivo (Adler et al., 2001). Previously, it has been
shown that passage of wild type gHV68 BAC through Vero-
Cre cells results in viral stocks which lack BAC vector
sequence and behave as wild type virus in vitro and in vivo
(Moorman et al., 2003).
M4 is dispensable for lytic viral replication in vitro, but has a
modest impact on acute replication in vivo
The ability to generate viral stocks following transfection of
M4.STOP BAC DNA into the Vero-Cre cell line indicated that
M4 is not essential for in vitro gHV68 lytic replication. To
quantitatively measure the growth kinetics of each virus in
vitro, M4.STOP, M4.MR, and wild type BAC-derived virus
were compared side by side over multiple rounds of viral
replication. NIH 3T12 fibroblasts were infected at a multiplic-
ity of infection (MOI) of 0.05 plaque forming units (pfu) per
cell with either M4.STOP, M4.MR or wild type virus, and titers
were determined over a 96-h time course. As shown in Fig. 4A,
M4.STOP, M4.MR, and wild type virus replicated to equiva-
lent titers with similar kinetics over the course of the assay.
Thus, M4 is not required for efficient lytic replication in vitro,
as expected based on the previously characterized in vitro
growth kinetics of gHV68 D9473 and MHV-76 (Clambey et
al., 2002; Macrae et al., 2001).
Although dispensable in vitro, M4 could play a role during
acute replication in vivo. To assess this possibility mice were
infected with 1103 pfu intranasally, and the amount of
preformed virus present in the lung was determined on days 4
and 9 post-infection. Mice infected with M4.STOP, M4.MR, or
wild type virus contained slightly different levels of virus in
lungs at both time points. At day 4 post-infection, M4.STOP
virus produced variable titers that did not differ significantly
from those produced by M4.MR, and wild type virus, while at
day 9 post-infection, lungs from M4.STOP infected animals
were found to contain approximately 5-fold less virus than
lungs from control infected animals (Fig. 4B).
Therefore, the absence of M4 appears to slightly alter the
dynamics of acute virus replication in the lung post-intranasal
inoculation.
M4 is required for the efficient establishment of latency at early
times post-infection after intranasal inoculation
To determine whether M4 plays a role during latent
infection, mice were infected intranasally with 1103 pfu of
M4.STOP, M4.MR, or wild type virus. Significantly less
Fig. 3. Schematic of M4 mutant virus construction and probes. (A) Wild type gHV68 was mutagenized to contain a translational stop codon immediately following
the initiating methionine of the M4 open reading frame. In addition, a single base pair was inserted following the stop mutation to shift the frame of the M4 ORF in
the event of read through of the stop codon. The sum of these two mutations introduces a unique AclI site into the M4 locus. The mutations in the M4 locus were
rescued to wild type sequence to generate the M4.MR virus to confirm that the phenotypes observed were specific to the M4 mutation, and not the result of spurious
mutations introduced during the mutagenesis process. The black bar denotes the location of the probe used for the Southern blot shown in panel B. (B) Southern blot
showing the genomic structure of the M4 region in wild type, M4.MR, and M4.STOP viruses. Wild type, M4.MR, and M4.STOP BAC DNA was digested with
HindIII (H), AclI (A), or SacII (S) and Southern blot performed using the probe described above. With all three viruses, digestion with HindIII or SacI results in a
fragments of 4838 and 9570 base pairs, respectively, confirming that the gross structure of the region is intact in all three BACs. The mutation in M4.STOP results in
the introduction of a novel AclI site. Thus, the AclI site in the M4.STOP genome results in the generation of two fragments that hybridize to the probe, of 6442 and
3394 base pairs in size, while a 9816 base pair AclI fragment is generated with wild type and M4.MR viruses. The observed higher molecular weight bands present in
many of the lanes reflect partial digestion of the BAC DNA into fragments too large to discern at this resolution.
A.G. Evans et al. / Virology 344 (2006) 520–531524splenomegaly was observed at 16 days post-infection in
animals infected with virus containing the M4.STOP allele as
compared to wild type (179.7 T 15.8 mg/spleen versus 303.8 T
15.7 mg/spleen, respectively, mean T SEM). The frequency of
cells reactivating virus was determined at days 16 or 42 post-
infection by harvesting splenocytes and performing a limiting
dilution assay as previously described (Weck et al., 1996).
Infected cells were co-incubated with an indicator monolayer
and subsequently scored for the cytopathic effect (CPE) that
results from reactivating virus. The frequency of splenocytes
harboring viral genome was also determined using a limiting
dilution PCR assay capable of detecting a single copy of the
viral genome in a background of 1104 uninfected cells
(Weck et al., 1996). As shown in Fig. 5A, at early times post-
infection, splenocytes from mice infected with M4.STOP were
found to exhibit an approximately 10-fold decrease in the
frequency of cells reactivating virus as compared to M4.MR or
wild type virus infected mice. This observed decrease in
reactivation closely correlated with the presence of 10-foldfewer viral genome-positive cells in the spleens of M4.STOP
infected mice compared to wild type or M4.MR infected mice
(Fig. 5B), indicating the decreased frequency of reactivation
fully reflects a defect in the establishment of splenic latency at
this time point.
At late times post-infection (e.g., 42 days), it was not
possible to accurately determine the frequency of cells
reactivating virus using the limiting dilution assay, as the
frequency of reactivating cells was too low (Fig. 5C). However,
by day 42 post-infection the frequency of viral genome-
positive cells in the spleen was nearly identical in mice infected
with either M4.STOP, M4.MR, or wild type virus (Fig. 5D).
Notably, at this time point the frequency of M4.STOP genome-
positive cells had not substantially changed in the intervening 4
weeks since the day 16 analysis, while the frequency of
M4.MR and wild type genome-positive cells decreased
approximately 10-fold over this time interval (compare Figs.
5B and 5D). These results indicate that, while important for the
efficient establishment of latency at early times post-infection
Fig. 4. In vitro and in vivo replication of M4.STOP, M4.MR, and wild type
virus. (A) NIH 3T12 cells were infected at an MOI of 0.05, and wells were
harvested at the indicated time points. Virus titers were quantitated by plaque
assay on 3T12 monolayers (see Materials and methods) Wild type, M4.MR,
and M4.STOP viruses were found to replicate to equivalent titers with similar
kinetics. The data represent the sum of two experiments, with the error bars
denoting the standard error of the mean. (B) Six- to 8-week-old C57Bl6/J mice
were infected with 1103 pfu of each virus intranasally. Lungs were harvested
at days 4 or 9 post-infection, homogenized, and the amount of virus quantitated
by plaque assay on 3T12 monolayers (see Materials and methods). Three-fold
more virus was found in the lungs of mice infected with M4.STOP as compared
to mice infected with either wild type or M4.MR virus at day 4 post-infection,
but this difference was not statistically significant (P value  0.0566). At day 9
post-infection, the lungs of mice infected with M4.STOP virus contained 5-fold
less virus than lungs from mice infected with M4.MR or wild type virus (*P
value  0.0397, unpaired, one-tailed P value). The data were compiled from
two separate experiments, with four to five mice per group per experiment. The
black bar denotes the mean titer of the group.
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maintenance of latency in vivo.
Loss of M4 alters splenic latency following intraperitoneal
inoculation, but does not affect establishment of latency in
peritoneal cells
The transient defect in the establishment of splenic latency
observed with the M4 mutant led us to question whether a
delay in trafficking of virus to the spleen could explain the
observed phenotype. By altering the route of infection, we
hoped to observe a differential requirement for M4 function.
Intraperitoneal infection alters the trafficking requirements for
the establishment of splenic latency, as B cells are required for
splenic latency after intranasal but not intraperitoneal infection(Usherwood et al., 1996b; Weck et al., 1996). The intraperi-
toneal route also provides for robust latent infection outside of
the spleen, as PECs are directly infected and subsequently
harbor latent virus presumably without any requirement for
trafficking of infected cells. We have previously observed
phenotypes that are dependent upon both the inoculation route
and anatomic site of infection in the establishment of gHV68
latency (Herskowitz et al., 2005; Jacoby et al., 2002). In order
to explore this possibility for M4, mice were infected with
1103 pfu of either M4.STOP, M4.MR, or wild type virus via
intraperitoneal inoculation. Both splenocytes and PECs were
analyzed at 16 days post-infection as described above.
Splenocytes from mice infected with M4.STOP demonstrated
a ca. 10-fold decrease in the frequency of cells reactivating
virus (Fig. 6A), similar to the defect observed post-intranasal
inoculation. Notably, the frequency of M4.STOP-infected
splenocytes harboring viral DNA was only decreased by ca.
3-fold (Fig. 6B), suggesting that there may be a slight
reactivation defect following intraperitoneal inoculation that
was not observed following intranasal inoculation (Table 1).
However, there was sufficient variability in the reactivation
analyses to make this subtle difference difficult to discern (see
Fig. 6A).
Direct infection of the peritoneal cavity leads to the
establishment of latency within PECs, primarily in macro-
phages (Weck et al., 1999b). In contrast to the observed defect
in the establishment of latency with the M4.STOP virus in the
spleen, examination of the PECs revealed no affect of loss of
M4 as both the frequency of latently infected cells reactivating
virus and containing viral DNA were equivalent between
animals infected with M4.STOP and control viruses (Figs. 6C
and D). Thus, either the difference in predominant cell type
harboring latent virus within the peritoneal cavity, and/or the
absence of virus trafficking obviates the requirement for M4
function.
Discussion
Here, we report a preliminary characterization of the M4
protein and the first analysis of the role of the M4 gene
during gHV68 pathogenesis. In confirmation of previous
work (Ebrahimi et al., 2003; Martinez-Guzman et al., 2003;
Townsley et al., 2004), the M4 transcript was found to be
expressed at early times post-infection. Based on single-
stranded Northern blot analyses, we confirmed that the M4
protein initiates from the second methionine in the predicted
ORF (Townsley et al., 2004; Virgin et al., 1997). This protein
product was secreted from cells transfected with an M4
expression construct, and the secreted product was modified
by the addition of N-linked glycans. M4 is the second viral
gene product encoded by gHV68 to be identified as a
secreted molecule, along with the M3 chemokine binding
protein (van Berkel et al., 2000; van Berkel et al., 1999).
Disruption of the M4 ORF by the introduction of a
translational termination codon immediately following the
initiating methionine did not significantly affect lytic replica-
tion in vitro. It did, however, modestly alter the dynamics of
Fig. 5. Analysis of latent splenocyte infection following intranasal infection with M4.STOP, M4.MR or wild type virus. Six- to 8-week-old C57Bl6/J mice were
infected with 1103 pfu via intranasal inoculation. Splenocytes were harvested either 16 or 42 days post-infection. (A, C) Splenocytes were plated onto murine
embryonic fibroblast (MEF) monolayers in a limiting dilution assay to determine the frequency of cells reactivating virus. (B, D) Limiting dilution PCR analysis of
splenocytes from the same mice used in panel A, C was performed to determine the frequency of cells harboring viral genome. At day 16 post-infection, M4.STOP
infected splenocytes exhibited a ca. 10-fold defect in the both the frequency of cells reactivating virus and the frequency of viral genome-positive cells. While we did
not detect significant reactivation from latency at day 42 post-infection, the frequency of viral genome-positive cells was comparable among all three viruses. The
results of the frequency analysis are displayed in Table 1. The data were compiled from three independent experiments, with five mice per group per experiment.
A.G. Evans et al. / Virology 344 (2006) 520–531526acute lung infection in vivo. The extent to which a mild
replication defect impacts the ability of the virus to establish
latency is an open question. However, we have previously
failed to observe a significant impact of virus dose on the
establishment of latency even though it substantially impacts
lytic virus replication in the lungs (Tibbetts et al., 2003). In
addition, recent data indicate that establishment of latency in
the lung occurs as early as 2 to 3 days post-infection (Flano et
al., 2005), at a time when we did not observe any defect in
acute replication of the M4.STOP virus in the lungs of
infected mice. Thus, it seems unlikely that the modestTable 1





i.n. splenocytes M4.STOP 1/15,654
M4.MR 1/1943
WT 1/1665
i.p. splenocytes M4.STOP 1/21,323
M4.MR 1/2100
WT 1/2647
i.p PECs M4.STOP 1/5142
M4.MR 1/7357
WT 1/3415
a Intranasal (i.n.) and intraperitoneal (i.p.) inoculation.
b Frequency analysis was based on the application of the Poisson distribution to th
are estimated to contain positive events represents the frequency at which those ev
c Reactivation efficiency was determined by calculating the ratio of the frequencdecrease in virus replication in the lung observed at day 9
post-infection with the M4.STOP virus has a significant
impact on the establishment of latency.
Following intranasal inoculation, loss of M4 function
decreased the frequency of viral genome-positive cells in the
spleen by 90%, although this defect was no longer evident by 6
weeks post-infection. It is possible that the early defect in
splenic latency is the result of delayed trafficking of latently
infected cells from the lung to the spleen based on several
factors: (i) the defect was temporary, (ii) M4 impacted early













e limiting dilution data in Figs. 5 and 6. The cell count at which 63.2% of wells
ents occurred.
y of reactivating cells to the frequency of genome-positive cells.
Fig. 6. Analysis of latent splenocyte and PEC infection following intraperitoneal infection with M4.STOP, M4.MR, and wild type virus. Six- to 8-week-old C57Bl6/J
mice were infected with 1103 pfu via intraperitoneal inoculation. Splenocytes and PECs were harvested at 16 days post-infection and subjected to limiting dilution
analysis to determine the frequency of reactivation and genome-positive cells. (A) Splenocytes infected with M4.STOP exhibited a ca. 10-fold decrease in the
frequency of ex vivo reactivation. (B) The frequency of genome-positive splenocytes infected with M4.STOP was diminished ca. 3-fold. (C, D) M4.STOP-infected
PECs exhibited no significant difference in the frequency of ex vivo reactivation or genome-positive cells compared to M4.MR and wild type virus. The results of the
frequency analysis are displayed in Table 1. The data were compiled from two or three independent experiments, with five mice per group per experiment.
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and (iv) M4 transcription is immediate-early and predominant-
ly within sites of acute infection (Simas et al., 1999; Virgin et
al., 1999). Other possible explanations include a role for M4 in
modulating immune clearance of latently infected cells, or that
it is involved in proliferation of latently infected cells. With
respect to the latter, we have recently shown that B cell
proliferation is a critical aspect of establishment of gHV68
latency in the spleen (Moser et al., 2005). To examine the
possibility of a trafficking phenotype, an alternative route of
infection was chosen. Intraperitoneal inoculation alters the
trafficking requirements for the establishment of splenic
latency as compared to intranasal infection; B cells are required
for trafficking virus from the lung to the spleen (Usherwood et
al., 1996b), but they are not required to establish splenic
latency following intraperitoneal infection (Weck et al., 1996).
In addition to altering trafficking requirements for splenic and
PEC latency, intraperitoneal inoculation provides a means of
comparing cell type-specific requirements of latency. The
predominant cell type harboring latent infection differs
between the spleen and peritoneal cavity—B cells represent
the majority of latently infected cells in the spleen (Willer and
Speck, 2003), while macrophages comprise the bulk of
peritoneal latency (Weck et al., 1999b). Following intraperito-
neal inoculation, the M4.STOP virus was able to establish and
reactivate from PEC latency equivalent to wild type and
M4.MR rescue viruses, but splenic latency was diminished.
This difference may be attributed to either the predominant celltypes infected in the PECs versus spleen, or the relative
contribution of direct infection versus systemic spread upon
establishment at each anatomical site, respectively. The defect
that did occur in intraperitoneal splenic latency was not as
substantial as after intranasal inoculation, which may reflect
some commonalities, but also differences, in the requirements
for trafficking to the spleen that are inherent to each route of
infection.
A role for M4 in gHV68 reactivation from latency is
considered unlikely. M4.STOP virus produced no detectable
change in PEC reactivation, nor was the reactivation efficiency
decreased following intranasal inoculation (Table 1). It is
known that the overwhelming majority of reactivating virus
from explanted splenocytes arises from latently infected B cells
(Marques et al., 2003; Willer and Speck, 2003). The fact that
M4.STOP displays no reactivation defect after intranasal
inoculation, but exhibits a slight reactions defect following
intraperitoneal infection, suggests the virus is less reliant on
M4 function for seeding the spleen which B cells are not
required. While the use of intraperitoneal infection did not
conclusively demonstrate a role for M4 in the trafficking of
latently infected virus to the spleen, it did distinguish a
requirement for M4 function in different cell populations. The
ability of the M4 gene product to impact the initial
establishment of splenic latency also provides further evidence
that the significant changes in latency associated with the
pathogenesis of the gHV68 D9473 and MHV76 viruses are the
result of combinatorial effects. The extent to which any of the
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with one another is currently under investigation.
Some important differences exist between the approach
taken here to assess M4 function and those previously reported
(Townsley et al., 2004). The previous analysis depended upon
a recombinant virus constructed from MHV-76 (Macrae et al.,
2001), which lacks the same 9.5 kb region which is deleted in
the D9473 gHV68 mutant. Townsley et al. (2004) reported that
insertion of a 3.5-kb of genomic sequence, which includes the
M4 ORF as well as 995 bp of ‘‘noncoding’’ upstream sequence
(containing putative M4 cis-regulatory elements) and 1,129 bp
of sequence downstream of the M4 translation stop codon, into
the MHV-76 genome produced a recombinant virus
(MHV76inM4) that partially restored features of gHV68
latency. This result suggested that the product of the M4
ORF plays a role during latency. However, several problems
exist with this approach. First, the impact of genetic sequences
located outside the M4 ORF was not addressed in this study.
Upstream sequences introduced into the MHV-76 genome may
have affected latency, as the authors’ transcriptional analysis of
M4 expression in this recombinant virus revealed appreciable
differences compared to gHV68. The degree of cyclohexamide
induced repression of M4 transcription varied between gHV68
and MHV76inM4, and M4 transcription in vivo was detected
at much later time points from the MHV76inM4 virus. Second,
the study of MHV76inM4 lacked a targeted disruption of the
M4 ORF, and thus differences observed between MHV76 and
MHV76inM4 have not been conclusively mapped to M4 gene
expression. Finally, characterization of the M4 ORF in the
absence of several genes important for gHV68 latency does not
allow an evaluation of the contribution of the M4 gene product
to viral latency in its natural genetic context. Our analysis
demonstrates M4 is required to establish normal latent load
specifically in a splenocyte population, consistent with a B cell
deficit. In light of this finding, the MHV-76 in M4 study is
severely limited by the fact that the virus lacks a number of
viral genes that impact pathogenesis, namely M1 and M2
which have been shown to be important modulators of gHV68
latency (Clambey et al., 2000; Jacoby et al., 2002; Macrae
et al., 2003).
The results presented here are consistent with a role for M4
in helping to efficiently traffic latent virus to the spleen, but
they do not rule out other explanations. Broadly, it is tempting
to speculate that the role of the secreted protein is to modulate
the host immune system based on the observation that many
non-essential herpesvirus genes act in this capacity. The
neighboring M3 gene has been shown to encode the most
abundantly secreted viral protein following gHV68 infection
(van Berkel et al., 1999). Several studies have shown that the
M3 protein is involved in binding to host chemokines secreted
in response to infection (Alcami, 2003; Jensen et al., 2003; Seet
and McFadden, 2002; van Berkel et al., 2000). Surprisingly,
the absence of M3 does not have an appreciable impact on
gHV68 latency (van Berkel et al., 2002). Perhaps, the M4
protein binds to host chemokines which localize infected cells
to the site of lytic infection. In the absence of M4, infected cells
which would normally traffic to the spleen remain trapped atthe site of infection. Following resolution of the initial
inflammatory event and subsequent down regulation of the
interacting chemokine, the infected cells would be free to
traffic to the spleen, thus explaining the equivalent numbers of
viral genome-positive cells found in the spleens of mice
infected with M4.STOP, M4.MR, and wild type virus at late
times post-infection. Alternatively, M4 could mimic chemokine
activity and act as a recruitment factor responsible for eliciting
migration of a specific cell population to the lung that is
required for dissemination to the spleen. A similar paradigm
has been shown to occur in murine cytomegalovirus (MCMV),
a member of the h-herpesvirus family. MCMV encodes a CC
chemokine homolog, MCK-2, that is responsible for recruiting
leukocytes to the footpad site of infection thereby providing a
vehicle for efficient dissemination and trafficking to the
salivary glands (Noda et al., 2005; Saederup et al., 1999,
2001). Outside of this realm, the secreted M4 protein could
modulate host responses by acting as a ligand agonist or
antagonist for any of the numerous regulatory receptors of the
immune system. The fact that M4 expression is much less
abundant than M3 and seems to occur within more limited
tissues and cell types in vivo, yet appreciably impacts viral
latency where as M3 does not, may be seen to support this
latter notion. Studies are currently under way to determine the
function of the secreted M4 protein.
Materials and methods
Viruses and tissue culture
Viral stocks were generated by transfecting gHV68 BAC
clones into Vero-Cre cells. Following the appearance of
cytopathic effect, wells were harvested and used to infect
Vero-Cre cells to generate high titer viral stocks. NIH 3T12
cells and mouse embryonic fibroblasts (MEFs) were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal calf serum, 100 U of penicillin
per ml, 100 mg of streptomycin per ml, and 2 mM l-glutamine
(complete DMEM). Cells were maintained in a 5% CO2 tissue
culture incubator at 37 -C. MEFs were obtained from either
BALB/c or C57BL/6 mouse embryos as described previously
(Weck et al., 1996). Vero-Cre cells were a gift from Dr. David
Leib. Cells were passaged in DMEM supplemented with 10%
fetal calf serum and 300 Ag/ml Hygromycin B.
RNA preparation and Northern blotting
NIH 3T12 fibroblasts were infected with WT virus at a
multiplicity of infection of 5. At 2, 4, 8, 16, and 24 h post-
infection, total RNA was harvested by single-step isolation as
previously described (van Berkel et al., 1999). Briefly, cells
were harvested into 7 ml GITC-phenol (10:1:10 mixture of the
following: [i] 4M guanidine isothiocyanate, 0.1 M mercap-
toethanol, 0.5% sarcosyl, [ii] 2M sodium acetate pH 4.0, [iii]
H20-saturated phenol). Samples were chloroform extracted,
and the upper aqueous phase was isopropanol precipitated.
RNA was stored in 75% ethanol at 80 -C until needed.
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described (van Berkel et al., 1999). Briefly, 5 Ag of total
RNA was loaded into each lane of a 1.5% agarose, denaturing
gel. As a basis for size comparison, 2.5 Ag of an RNA ladder
(New England Biolabs, Beverly, MA) was run alongside. RNA
was transferred to a nylon membrane overnight, prehybridized
for at least 1 h, and hybridized with radiolabeled probe for up
to 18 h at 42 -C. Washes were performed at 55 -C for 30 min
each, twice with 2SSC/0.1% SDS, and once with 0.2SSC/
0.1% SDS. Blots were visualized either by exposure to X-Omat
Blue film (Kodak, Rochester, NY) and development on a
Konica SRX-101 Film Processor, or by exposure to a Storage
Phosphor Screen and development on Typhoon 9410 Variable
Mode Imager (Amersham Biosciences).
Double-stranded DNA probes were generated using the
Megaprime DNA Labelling System (Amersham Biosciences)
to generate [32P]-labeled nucleic acid from the 747 bp SpeI/
PvuII restriction endonuclease fragment contained within the
M4 ORF. Single-stranded DNA probes, matched for identical
G+C content, were designed to correspond to two 50-bp
stretches upstream and downstream of the second ATG codon
in the M4 ORF (genomic coordinates 8447–8495 and 8621–
8669, respectively, Genbank Accession #NC 001826). Anti-
sense (a-s, complimentary to mRNA) and sense (s) oligonu-
cleotides were generated for each region. Oligonucleotide
sequences were the following: 8447–95 a-s, 5V-CCA AAA
ATT CTA TTG GGC AAT CAG GGA TGA TCT AAT TAT
CCA TGG AGG C-3V; 8447–95 s, 5V-GCC TCC ATG GAT
AAT TAG ATC ATC CCT GAT TGC CCA ATA GAA TTT
TTG G-3V; 8621–69 a-s, 5V-AGA AGA TGA TGA TAT TCC
TGT AAA AAT CCA TCG GCT GAC CTT CGT GAA G-3V;
8621–69 s, 5V-CTT CAC GAA GGT CAG CCG ATG GAT
TTT TAC AGG AAT ATC ATC ATC TTC T-3V. 10 pmol of
each oligonucleotide was end-labeled with [32P] in a polynu-
cleotide kinase (New England Biolabs) reaction, per manufac-
turer’s instructions, and probes were purified over G-25
Sephadex columns (Roche, Indianapolis, IN). Single stranded
probes were determined to have comparable levels of [32P]
incorporation.
Western blot, immunoprecipitation, and glycosidase assay
M4 coding sequence (genomic coordinates 8538–9785)
was PCR amplified from gHV68 BAC DNA, incorporating a
SacI restriction site and Kozac sequence immediately upstream
of the translational start site and a XhoI restriction site
immediately downstream of the last codon. Primer sequences
were the following: 5V-TCG AAC GAG CTC GCC GCC ATG
GTG GGC ACC CAG CCT AG-3V and 5V-GGT TGC CTC
GAG TTC TAG AAA GTC ATA AAT CTC-3V. PCR products
were cloned into pCR-Blunt (Invitrogen, Carlsbad, CA),
sequenced to confirm fidelity, and subcloned into the SacI
and XhoI sites of the pCMV-Tag4B epitope-tagging mamma-
lian expression vector (Stratagene, Cedar Creek, TX). The M3
expression vector was generated in an identical manner, using
primer sequences that correspond to genomic coordinates
6060–7277. The v-cyclin expression vector was generatedby cloning sequence corresponding to genomic coordinates
102,423–103,181 into pCMV-Tag2B (Stratagene).
Expression vectors were transfected into Cos-1 cells using
TransIT-LT1 Reagent (Mirus, Madison, WI), per manufac-
turer’s instructions. After 48 h, transfected cell supernatants
were removed and immunoprecipitated overnight using 30
Al ANTI-FLAG M2-agarose affinity gel (Sigma, St. Louis,
MO). Cells lysates were prepared by the addition of E1A lysis
buffer (50 mM HEPES pH 7.2, 250 mM NaCl, 2 mM EDTA,
and 0.1% NP-40) followed by a twenty min incubation.
Western Blots were performed according to standard protocol.
Briefly, whole cell lysates and immunoprecipitates were
denatured and separated by SDS-PAGE and transferred to
nitrocellulose membrane. Nitrocellulose was blocked for 1 h at
room temperature, immunoblotted overnight at 4 -C with
ANTI-FLAG M2-peroxidase conjugated antibody (Sigma), and
antibody was detected using ECLWestern blot analysis System
(Amersham Biosciences, Buckinghamshire, UK). Endoglyco-
sidase susceptibility was determined by incubating immuno-
precipitated protein with either Endoglycosidase H (Endo Hf)
or N-glycosidase F (PNGase F) (New England Biolabs) per
manufacturer’s instructions.
Construction of M4.STOP and M4.MR viruses
To assess the requirement for the M4 protein during gHV68
infection, we constructed a gHV68 mutant in which the M4
open reading frame is disrupted by a translational stop codon
immediately following the initiating methionine (M4.STOP).
The M4.STOP virus was constructed using allelic exchange in
RecA-positive E. coli (GS500), as described previously
(Moorman et al., 2003). Briefly, overlap PCR was used to
mutate the codon immediately following the identified initiat-
ing methionine to a translation termination codon, and an extra
base was inserted downstream of the stop codon to frameshift
the rest of the reading frame in the event of translational read-
through of the stop mutation. PCR was performed with Vent
polymerase, which has proofreading activity. The wild type
sequence was 5V GCG ATG GGA CCG TTA GGA AGA CC 3V
and the sequence of the mutant is 5VGCG ATG TGA ACG TTA
tGG AAG ACC 3V. The translational stop is shown in italics,
and the inserted base is indicated by lowercase type. This
mutation also results in the formation of a novel AclI restriction
site (underlined). The coordinates for the wild type sequence
listed correspond to genomic sequences 8535 to 8557. The
PCR product was cloned into the suicide vector pGS284, and
allelic exchange was performed with this vector and wild type
BAC to generate the M4.STOP BAC. To confirm that the
phenotypes observed were the result of the M4 mutation and
not a second site mutation, the mutation in M4.STOP was
rescued to wild type sequence (M4.MR) using the same
methodology. Genomic sequences 7828 to 9178 were ampli-
fied and cloned into pGS284, and allelic exchange was
performed with this vector and the M4.STOP BAC. Rescue
of the mutation was checked by PCR, then the structure of all
recombinant BACs were confirmed by restriction digest with
AclI and detection by Southern blot (Fig. 3). The same PCR
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random priming and used as the probe for the diagnostic
Southern blot. As PCR was used to generate the recombination
targeting vectors, the sequences of the M4.STOP and M4.MR
targeting vectors were confirmed by sequencing prior to
recombination.
Mice, infections, and organ harvests
C57BL/6 mice were purchased from the Jackson Laborato-
ries and used between 8–12 weeks of age. Mice were placed
under isofluorane anesthesia prior to infection, as well as
before sacrifice by cervical dislocation. Intranasal inoculations
were performed in a volume of 20 Al complete DMEM, while
intraperitoneal inoculations consisted of 200 Al. Upon sacrifice,
lungs were placed in 0.5 ml of complete DMEM and frozen at
80 -C. Sentinel mice were assayed every 3 months and were
negative for adventitious mouse pathogens by serology.
Plaque assays
Plaque assays were performed using NIH 3T12 monolayers
under noble agar overlay as described previously (Weck et al.,
1999a), with the following alterations. NIH 3T12 cells were
plated in 6-well plates at 2105 cells per well the day prior to
infection. Organs to be titered were thawed, homogenized by
mechanical disruption in a Mini-Beadbeater 8 (Biospec Pro-
ducts, Bartlesville, OK), and then 10-fold dilutions made in
complete DMEM were plated onto NIH 3T12 cell monolayers.
Infections were performed in a 200-Al volume and plates were
rocked every 15 min for 1 h at 37 -C. Samples were overlaid
with 3 ml of a 1:1 mixture of 3% noble agar and 2 MEM
supplemented with 20% FCS and 2 concentration of
antibiotic and l-glutamine. An additional 2 ml of noble agar,
2 MEM mixture was added on day 3 post-plating. Mono-
layers were stained between day 6 and 8 by the addition of 2 ml
of neutral red overlay (0.01% neutral red in serum-free
DMEM). After 18–24 h, plaques were counted. The limit of
detection for this assay is 50 PFU per organ.
Limiting dilution ex vivo reactivation assay
Detection of gHV68 reactivation from latency was per-
formed as previously described (Weck et al., 1999a). Briefly,
splenocytes and PECs were harvested on days 16 or 42 post-
infection, and single cell suspensions were generated. Spleen
samples underwent erythrocyte lysis with ammonium chloride,
and all cells were resuspended in complete DMEM and plated
in a series of 2-fold dilutions, starting at 1105 cells per well,
onto MEF monolayers in 96-well tissue culture plates. After 21
days, wells were scored microscopically for the presence of
CPE. In some cases, samples were replated on fresh MEF
monolayers to confirm the presence of infectious virus. 24
wells were plated per dilution with a total of 12 dilutions per
sample per experiment. To detect preformed infectious virus,
parallel samples were resuspended in 1/3 DMEM in the
presence of 0.5 mm silica beads and subjected to four rounds ofone min mechanical disruption in a Mini-Beadbeater-8 as
previously described. This disruption procedure kills >99% of
cells, with at most a 2-fold effect on the titer of preformed
infectious virus (Weck et al., 1999a). Disrupted cells were
plated in a similar series of 2-fold dilutions.
Limiting dilution nested PCR detection of cHV68
genome-positive cells
We determined the frequency of cells containing gHV68
genome using a previously described nested PCR assay (LD-
PCR) with ca. single copy sensitivity to detect gene 50 of
gHV68 (Weck et al., 1999a). Briefly, splenocytes and PECs
were harvested from latently infected mice and frozen in
complete DMEM with 10% DMSO at 80 -C, thawed,
counted, resuspended in an isotonic solution, and diluted in a
background of 1104 uninfected NIH 3T12 cells. After
overnight lysis of cells with proteinase K, a first round PCR
was performed on each sample. Subsequently, second round
reaction mix was added directly to the first round and cycles
performed. Products were analyzed by ethidium bromide
staining of a 2% agarose gel. Twelve PCR reactions were
performed for each cell dilution with 6 dilutions per sample per
experiment. With each set of samples, 6 water controls and 18
controls for PCR sensitivity were included. To quantitate PCR
sensitivity, 10, 1 or 0.1 copies of a gene 50 containing plasmid
(pBamHI N) were diluted into a background of 1104
uninfected cells. This PCR protocol can detect a single copy
of a gene 50 containing plasmid (pBamHI N) diluted in a
background of carrier DNA and 1104 uninfected cells with
¨50% frequency.
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